Ancient herbal mix gets modern test for Crohn's
NCT ID NCT03992469
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-phase trial is testing the safety of an oral herbal formula called E-B-FAHF-2 in 7 adults with mild-to-moderate Crohn's disease. The formula is a concentrated version of a traditional Chinese medicine blend originally developed for food allergies. Researchers want to see if it is safe and tolerable, and whether it might help control inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
E-B-FAHF-2 (a concentrated herbal formula)
What this could lead to
If safe and effective, this could point toward a new treatment option for mild-to-moderate Crohn's disease with fewer pills to take.
What could go wrong
This is a very early, small Phase 1 safety study with only 7 participants. It is not designed to prove the treatment works, and many early-stage trials do not lead to approved therapies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.